Alopecia

 Mechanism:

• Most cytotoxic chemotherapy targets rapidly dividing cells.
• Hair follicle matrix keratinocytes are among the fastest dividing cells → highly susceptible to chemotherapy.
• Results in temporary hair loss, usually 2–3 weeks after starting therapy, with regrowth after treatment completion.

Drugs Commonly Causing Alopecia:

• High risk: Anthracyclines (doxorubicin, epirubicin), Taxanes (paclitaxel, docetaxel), Alkylating agents (cyclophosphamide, ifosfamide), Etoposide, Vinca alkaloids (vincristine, vinblastine).
• Low risk / rare: Antimetabolites (methotrexate, 5-FU, cytarabine), monoclonal antibodies, TKIs.

Clinical Characteristics:

• Onset: 1–3 weeks after treatment initiation.
• Extent: Can be patchy or complete (scalp, eyebrows, eyelashes, body hair).
• Reversibility: Usually reversible within 1–3 months after stopping chemotherapy.
• Patient impact: Significant psychosocial distress, body image concerns, reduced quality of life.

Prevention & Management:

• Scalp cooling (cold caps): Reduces blood flow to hair follicles during infusion → can reduce alopecia, especially with taxanes and anthracyclines.
• Patient counseling: Prepare patients before therapy; discuss temporary vs. permanent alopecia risk (e.g., higher risk of permanent loss with taxanes, busulfan, or radiation).
• Supportive care: Wigs, scarves, psychological support.
• No proven pharmacologic prevention (topical minoxidil may speed regrowth but not prevent loss).

Pharmacist Pearls:

• Alopecia is not life-threatening but can strongly affect adherence and quality of life.
• Always counsel proactively (before hair loss begins).
• Document baseline and monitor patient distress; refer to supportive resources if needed.
• Remind patients that regrown hair may differ in texture or color.

Do you want me to create a table of chemotherapy classes with their relative risk of alopecia (high, moderate, low, rare) for quick reference in practice?